論文

査読有り 国際誌
2021年11月1日

Clofarabine monotherapy in two patients with refractory Langerhans cell histiocytosis.

Cancer reports (Hoboken, N.J.)
  • Masahiro Irie
  • Tomohiro Nakano
  • Saori Katayama
  • Tasuku Suzuki
  • Kunihiko Moriya
  • Yuko Watanabe
  • Nobu Suzuki
  • Yuka Saitoh-Nanjyo
  • Masaei Onuma
  • Takeshi Rikiishi
  • Hidetaka Niizuma
  • Yoji Sasahara
  • Shigeo Kure
  • 全て表示

5
8
開始ページ
e1579
終了ページ
記述言語
英語
掲載種別
DOI
10.1002/cnr2.1579

BACKGROUND: Better therapeutic options other than conventional chemotherapy for pediatric patients with refractory Langerhans cell histiocytosis (LCH) remain undetermined. CASE: We successfully treated two patients with refractory and risk organ negative LCH with clofarabine (CLO) monotherapy after recurrence. We administered total 23 courses of CLO monotherapy in patient 1 and 4 courses in patient 2. Both patients had distinct clinical manifestations but achieved a durable complete response with acceptable adverse effects of transient myelosuppression. CLO monotherapy was still effective when he had the second recurrent lesion after first completion of CLO in patient 1. We could discontinue prednisolone to control his refractory inflammation of LCH after completing CLO chemotherapy in patient 2. CONCLUSION: Although large-scale studies are warranted, CLO monotherapy could be a therapeutic option for high efficacy and feasibility besides other intensive combination chemotherapies or allogeneic hematopoietic stem cell transplantation for refractory LCH without risk organ involvement in children.

リンク情報
DOI
https://doi.org/10.1002/cnr2.1579
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34725963
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351665
ID情報
  • DOI : 10.1002/cnr2.1579
  • PubMed ID : 34725963
  • PubMed Central 記事ID : PMC9351665

エクスポート
BibTeX RIS